Rhopressa, Rhokiinsa (netarsudil) is a small molecule pharmaceutical. Netarsudil was first approved as Rhopressa on 2017-12-18. It is used to treat ocular hypertension and open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. It is known to target rho-associated protein kinase 1 and rho-associated protein kinase 2. Rhopressa's patents are valid until 2034-03-14 (FDA).
|Indication||ocular hypertension, open-angle glaucoma|
|Drug Class||Vasodilators: Rho protein kinase (ROCK) inhibitors|